Given the associated costs and supported needed for PET (cyclotron), I doubt it will get much penetrance into the clinical market. Currently I see no use of any functional imaging clinically as differences can only be demonstrated across Dx with groups of patients, i.e. there is substantial (?>70%?) overlap in both patients and controls at the individual level, rendering its ability to indicate whether a specific pt is abnormal or not minimal. Both modalities continue to be useful for scientific study.
huh? Who pays for that? Does medicare reimburse that massive amount of money routinely for that indication? If so, just example #3430946723 why our health care system is in such a financial situation.
This site uses cookies to help personalize content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies and terms of service.